Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryHealthfirst exon-skipping DMD Coverage Prior Auth …
    Ask Trek AI about this page
    CurrentHealthfirstPolicy N/A

    Exon-skipping therapies for Duchenne muscular dystrophy (eteplirsen, golodirsen, casimersen, viltolarsen)

    Customize your policy alerts

    Sign up for all Healthfirst policy alerts

    Know when Healthfirst releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, medical necessity, dosing, monitoring, billing, and coverage criteria for exon-skipping antisense oligonucleotide therapies for patients with Duchenne muscular dystrophy (DMD) within Healthfirst plans.

    Policy Summary
    PayerHealthfirst
    PolicyExon-skipping therapies for Duchenne muscular dystrophy (eteplirsen, golodirsen, casimersen, viltolarsen)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2020
    Last ReviewMay 1, 2022
    Next Review DateN/A
    Key ActionObtain prior authorization with required documentation including diagnosis, genetic testing confirming amenable exon skipping, corticosteroid status, and kidney function testing (except for eteplirsen).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Up to 6 months
    Duration of approval per authorization
    30 mg/kg wklyDose (eteplirsen/golodirsen/casimersen)
    80 mg/kg wklyDose (viltolarsen)
    1 = 10 mgJ-code billing unit
    A-DIncluded appendices

    Coverage and Medical Necessity Criteria

    Initial therapy - Medical necessity criteria

    EXONDYS 51, VYONDYS 53, AMONDYS 45, and VILTEPSO are considered medically necessary when ALL of the following are met:

    Initial authorization criteria: 1) Patient has a diagnosis of Duchenne muscular dystrophy (DMD);
    Initial authorization criteria: 2) Genetic testing confirms the patient’s DMD gene mutation is amenable to exon 45, 51, or 53 skipping;

    Provide genetic test report documenting the exon deletion pattern (see Appendices B-D for examples).

    Initial authorization criteria: 3) Documentation confirms a stable dose of corticosteroids prior to initiating therapy, or documents a clinical reason the patient is not on corticosteroids;

    Include medication history and dates/doses to demonstrate stability or rationale for not using corticosteroids.

    Initial authorization criteria: 4) Documentation of kidney function testing prior to initiating therapy (except for eteplirsen, for which this testing requirement does not apply);

    Provide recent laboratory results (e.g., serum creatinine, eGFR) as part of prior authorization record; not required for eteplirsen.

    Initial authorization criteria: 5) Patient is not concurrently being treated with another exon skipping therapy for DMD;

    Concurrent use of multiple exon-skipping antisense oligonucleotides is not permitted.

    Coverage excludes use that exceeds the FDA-approved dosing specified in the dosing section of this policy. The policy also excludes initiation of other pharmacologic or experimental treatments that affect muscle strength or function within 12 weeks of the first week of exon-skipping therapy (with the exception of corticosteroids). Additionally, members with clinically significant comorbidities, and patients outside the trial populations (safety/efficacy unknown in females and geriatric patients) are subject to these limitations.

    Any violation of this policy will be handled in accordance with the plan’s Disciplinary Action policy.

    Eteplirsen, golodirsen, casimersen, and viltolarsen are considered investigational and not medically necessary when the specified medical necessity criteria are not met, or for any other indications beyond those defined by the policy. Coverage is contingent on meeting all required criteria such as diagnosis of DMD, genetic confirmation of an exon 45, 51, or 53 mutation amenable to skipping, documented corticosteroid status, and required kidney testing (except for eteplirsen).

    Billing, Codes, and Units

    Applicable J-codesHCPCS
    J1428Exondys 51 (eteplirsen) - 1 billable unit = 10 mg
    J1429Vyondys 53 (golodirsen) - 1 billable unit = 10 mg
    J1426Amondys 45 (casimersen) - 1 billable unit = 10 mg
    J1427Viltepso (viltolarsen) - 1 billable unit = 10 mg
    Infusion administration codesCPT | HCPCS
    96365IV infusion, initial, up to 1 hour
    96366IV infusion, each additional hour
    96601Home infusion/specialty drug administration, per visit (up to 2 hours)
    S9379Home infusion therapy, per diem (administrative/professional pharmacy services)
    Revenue codesRevenue
    0260IV therapy, general
    0636Drugs requiring detailed coding
    0510Clinic
    Diagnosis codesICD-10
    G71.01Duchenne or Becker muscular dystrophy
    Applicable NDCsNDC
    60923-0363-02Exondys 51 100mg/2ml
    60923-0284-10Exondys 51 500mg/10ml
    60923-0465-02Vyondys 53 single use vial
    60923-0227-02Amondys 45 100 mg/2 mL
    73292-0011-01Viltepso 250 mg/5 mL
    Billing units per vial (examples)mixed
    J-code billing units1 billing unit = 10 mg of drug; examples: Exondys 51 2 ml vial (100 mg) = 10 units; Exondys 51 10 ml vial (500 mg) = 50 units; Vyondys 53 2 ml vial (100 mg) = 10 units; Amondys 45 2 ml vial (100 mg) = 10 units; Viltepso 5 ml vial (250 mg) = 25 units
    6-Minute Walk Test (6MWT) distance — >325 meters association
    6MWT thresholdAbility to walk >325 meters on the 6-Minute Walk Test is associated with slower disease progression in DMD.
    Test descriptionMeasure of how far a patient can walk in six minutes on a hard, flat surface.
    Predictive useConsidered predictive of disease progression in muscular dystrophy patients over the age of one.

    Authorization, Documentation, and Billing Requirements

    Prior Authorization

    Prior Authorization and Peer Review Required

    Prior authorization required; subject to Healthfirst clinical criteria and peer review.

    • Peer review required due to expense of medication
    • Requests are reviewed against Healthfirst clinical criteria and applicable NCD/LCD
    Billing Rule

    J-code Billing Unit Reporting

    Provider must state number of J-code billing units on claim forms. For DMD drugs, 1 billing unit = 10 mg; incorrect or missing billing unit reporting may trigger claim issues or denials.

    • 1 billing unit = 10 mg of drug

    Background and Clinical Context

    Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder caused by deficiency of dystrophin, leading to progressive muscle fiber degeneration and weakness. Exon-skipping antisense oligonucleotide therapies (eteplirsen, golodirsen, casimersen, viltolarsen) are designed to exclude specific exons during mRNA processing to restore the dystrophin reading frame and produce a truncated but partially functional dystrophin protein. Prevalence of amenable mutations varies by exon (examples and mutation patterns are provided in the appendices).

    Key Definitions and Measures

    6-Minute Walk Test (6MWT) — definition and relevance
    DefinitionMeasure of how far a patient can walk in six minutes on a hard, flat surface.
    Clinical relevancePredictive of disease progression in muscular dystrophy and used to monitor functional status in DMD.
    Prognostic thresholdWalking distances greater than 325 meters have been linked to slower disease progression in DMD.
    Dystrophin — definition
    Protein roleDystrophin is a protein in muscle cells that helps strengthen muscle fibers and protect them from breaking down.
    Pathologic consequenceDeficiency in dystrophin leads to muscle breakdown and loss of function and is the primary defect in DMD.
    Policy Summary
    PayerHealthfirst
    PolicyExon-skipping therapies for Duchenne muscular dystrophy (eteplirsen, golodirsen, casimersen, viltolarsen)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2020
    Last ReviewMay 1, 2022
    Next Review DateN/A
    Key ActionObtain prior authorization with required documentation including diagnosis, genetic testing confirming amenable exon skipping, corticosteroid status, and kidney function testing (except for eteplirsen).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling, Codes, and UnitsAuthorization, Documentation, and Billing RequirementsBackground and Clinical ContextKey Definitions and Measures
  1. Examples: Exondys 51 100 mg vial = 10 units; 500 mg vial = 50 units; Vyondys 53 100 mg vial = 10 units; Amondys 45 100 mg vial = 10 units; Viltepso 250 mg vial = 25 units
  2. Prior Authorization

    Concurrent Therapy Restriction

    Patient must not be concurrently treated with another exon skipping therapy for DMD. Concurrent use with other exon skipping agents is not allowed.

    • Concurrent treatment with another exon skipping therapy for DMD is a contraindication to coverage
    Documentation Required

    Required Documentation for Prior Authorization

    Documentation to support prior authorization must include diagnostic and testing evidence as specified below; requests that fail to meet criteria may be denied.

    • Diagnosis of Duchenne muscular dystrophy (DMD)
    • Genetic testing confirming a DMD gene mutation amenable to exon 45, 51, or 53 skipping (see Appendices B–D)
    • Documentation of stable corticosteroid dose prior to initiation or a documented reason for not receiving corticosteroids
    • Baseline kidney function testing prior to initiation (except for eteplirsen)
    Documentation Required

    NSAA Scoring Documentation

    Include results from the North Star Ambulatory Assessment (NSAA) when submitting requests; document the activity item scores from Appendix A in the medical record and prior authorization submission.

    • Attach NSAA scores (Appendix A) or include them in the clinical documentation
    • Document individual activity item scores (e.g., Stand, Walk, Rise from chair, Climb, Jump, Run, Hop, etc.) and total score as applicable
    Denial Risk

    Denial for Unmet Criteria

    Requests failing to meet the medical necessity criteria may be denied. Ensure all required documentation and eligibility criteria are addressed on submission to avoid denials.

    • Denial may occur if genetic testing does not show an amenable mutation, required labs or NSAA scores are missing, or if concurrent exon skipping therapy is present
    • Duration of approval when approved: up to 6 months
    Step Therapy

    Step Therapy

    No step therapy requirements specified for these agents.

    • No step edits or prior required trials specified in policy
    Disease contextCentral molecular defect targeted by exon-skipping therapies for Duchenne muscular dystrophy.
    FVC — Forced vital capacity definition
    DefinitionForced vital capacity (FVC) is the volume of air in the lungs that can be exhaled following a deep inhalation, expressed in liters.
    Measurement useUsed to assess respiratory function and monitor pulmonary involvement in neuromuscular disease.
    Clinical contextDeclining FVC can indicate progressive respiratory impairment in DMD patients.
    NSAA — North Star Ambulatory Assessment definition
    DefinitionNorth Star Ambulatory Assessment (NSAA) is a 17-item rating scale used to measure functional motor abilities in ambulant children with DMD.
    PurposeUsually used to monitor disease progression and treatment effects.
    ApplicationAppendix A contains the NSAA activity item scoring used for documentation in prior authorization.
    J-code billing unit — One billing unit corresponds to 10 mg
    Unit definitionOne J-code billing unit corresponds to 10 mg of DMD drug administered.
    Claim requirementProviders must state the number of J-code billing units used on claim forms based on mg administered.
    PurposeUsed to convert vial milligrams to billing units for accurate claims and reimbursement.